What amount sold does Accera Inc report in Form D filings?

The latest linked filings report $162M sold across 10 identified offering(s). 1 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Accera Inc's most recent SEC filing?

Accera Inc's most recent Form D filing was on 2024-06-25.

How many investors does Accera Inc have?

The most recent Form D filing lists 10 investor(s).

What type of securities does Accera Inc offer?

Accera Inc's SEC Form D filings indicate debt offerings.

Accera Inc

CIK: 0001293610·Biotechnology·DENVER, CO·Corporation

Reported Sold

$161,951,375

Total Filings

Identified Offerings

Last Filed

Jun 25, 2024

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately. 1 unlinked amendment excluded.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jun 25, 2024Form D — New notice

Reported sold: $3,740,000 · Target: $7,000,000

Rule 506(b)·10 investors

Aug 18, 2022Form D — New notice

Reported sold: $7,220,002 · Target: $39,999,999

Rule 506(b)·1 investor

Sep 29, 2021Form D — New notice

Reported sold: $10,000,001 · Target: $30,000,000

Rule 506(b)·3 investors

Feb 5, 2021Form D — New notice

Reported sold: $10,000,000 · Target: $14,999,935

Rule 506(b)·1 investor

Mar 26, 2018Form D — New notice

Reported sold: $17,639,537 · Target: $50,139,527

Rule 506(b)·2 investors

Jan 21, 2014Form D/A — Amendment

Reported sold: $84,081,610 · Target: $84,081,610

Rule 506(b)·2 investors

Changed: Reported amount sold, Offering target

Oct 25, 2013Form D/A — Amendment

Reported sold: $79,081,610 · Target: $79,081,610

Rule 506(b)·2 investors

Changed: Reported amount sold, Offering target, Exemptions

May 7, 2013Form D/A — Amendment

Reported sold: $69,081,610 · Target: $69,081,610

Rule 506·2 investors

Changed: Reported amount sold, Offering target

Oct 12, 2012Form D/A — Amendment

Reported sold: $34,081,610 · Target: $34,081,610

Rule 506·2 investors

Changed: Reported amount sold, Offering target

Jul 27, 2012Form D — New notice

Reported sold: $18,397,296 · Target: $18,397,296

Rule 506·2 investors

May 24, 2012Form D — New notice

Reported sold: $3,900,787 · Target: $3,900,787

Rule 506·1 investor

May 24, 2012Form D — New notice

Reported sold: $4,882,125 · Target: $4,882,125

Rule 506·1 investor

Dec 21, 2010Form D — New notice

Reported sold: $11,000,000 · Target: $11,000,000

Rule 506·3 investors

Mar 15, 2010Form D — New notice

Reported sold: $9,487,313 · Target: $9,487,313

Rule 506·4 investors

Apr 23, 2009Form D/A — Amendment

Reported sold: $26,051,995 · Target: $35,170,200

No verified predecessor available.

Rule 506·4 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

33%

Latest reported sold across 10 identified offerings

$161,951,375

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

1 unlinked amendment excluded.

Key People

Gunnar Weikert

Related Person

Appears on 4 filings

Claude Nash

Related Person

Appears on 4 filings

Samuel T. Henderson

Related Person

Appears on 4 filings

Wolfgang Reichenberger

Related Person

Appears on 4 filings

Jerris Knaisch

Related Person

Appears on 4 filings

KiKab Kim

Related Person

Appears on 3 filings

Gurpreet Singh Vohra

Related Person

Appears on 3 filings

Hans-Jurgen Woerle

Related Person

Appears on 3 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jun 25, 2024	New	$7,000,000	$3,740,000	10
Aug 18, 2022	New	$39,999,999	$7,220,002	1
Sep 29, 2021	New	$30,000,000	$10,000,001	3
Feb 5, 2021	New	$14,999,935	$10,000,000	1
Mar 26, 2018	New	$50,139,527	$17,639,537	2
Jan 21, 2014	Amendment	$84,081,610	$84,081,610	2
Oct 25, 2013	Amendment	$79,081,610	$79,081,610	2
May 7, 2013	Amendment	$69,081,610	$69,081,610	2
Oct 12, 2012	Amendment	$34,081,610	$34,081,610	2
Jul 27, 2012	New	$18,397,296	$18,397,296	2
May 24, 2012	New	$3,900,787	$3,900,787	1
May 24, 2012	New	$4,882,125	$4,882,125	1
Dec 21, 2010	New	$11,000,000	$11,000,000	3
Mar 15, 2010	New	$9,487,313	$9,487,313	4
Apr 23, 2009	Amendment	$35,170,200	$26,051,995	4

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

GelSana Therapeutics, Inc.

Biotechnology

Offering target: $4,931,726

Filed Oct 8, 2026